![Brain stained with Pan TRK [RM423] antibody](https://biocare.net/wp-content/uploads/3267.jpg "Brain stained with Pan TRK [RM423] antibody")
![Glioblastoma stained with PAN TRK [RM423] antibody](https://biocare.net/wp-content/uploads/3267_C.jpg "Glioblastoma stained with PAN TRK [RM423] antibody")
![Diffuse astrocytoma stained with PAN TRK [RM423] antibody](https://biocare.net/wp-content/uploads/3267-B.jpg "Diffuse astrocytoma stained with PAN TRK [RM423] antibody")
![Brain stained with Pan TRK [RM423] antibody](https://biocare.net/wp-content/uploads/3267-247x296.jpg)
![Glioblastoma stained with PAN TRK [RM423] antibody](https://biocare.net/wp-content/uploads/3267_C-247x296.jpg)
![Diffuse astrocytoma stained with PAN TRK [RM423] antibody](https://biocare.net/wp-content/uploads/3267-B-247x296.jpg)
Pan TRK [RM423]
Price range: $615.00 through $2,150.00
Description
Product Description
The Biocare Pan TRK [RM423] rabbit monoclonal antibody targets the neurotrophic tyrosine receptor kinase (NTRK) proto-oncogenes. The NTRK proto-oncogenes NTRK1, NTRK2, and NTRK3 (that encode TRK A, TRK B, and TRK C proteins, respectively) may form gene fusions through their kinase domains, driving tumor development.15 TRK A is activated by nerve growth factor (NGF), TRK B by brain-derived neurotrophic factor (BDNF) or neurotrophin-4 (NT-4), and TRK C by neurotrophin3 (NT-3).16 NTRK fusions are characteristic of a few rare types of cancer, such as secretory carcinoma of the breast or salivary gland and infantile fibrosarcoma, but they are also infrequently seen in some common cancers, such as melanoma, glioma and carcinomas of the thyroid, lung and colon.17,18 The Pan TRK immunohistochemical staining may be useful in the aiding of classification of cancers exhibiting NTRK fusions.17,19
Specifications
Specifications
| Intended Use | |
|---|---|
| Format | Concentrate, NeoPATH Pro, ONCORE Pro, Predilute, Q Series, UltraLine |
| Volume | |
| Source | |
| Clone | |
| Species Reactivity | |
| Isotype | |
| Positive Control |
Datasheet & SDS
| Download Data Sheet |
| Download RUO Data Sheet |
| Download SDS Sheet |
Browse more documents for this product (IFUs, datasheets, translations, SDS, and more).
References
1. Hechtman JF, Benayed R, Hyman DM, et al. Pan-Trk immunohistochemistry is an efficient and reliable screen for the detection of NTRK fusions. Am J Surg Pathol. 2017;41(11):1547-1551.
2. Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018;15(12):731-747.
3. Solomon JP, Linkov I, Rosado A, et al. NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Mod Pathol. 2020;33(1):38-46.
4. Solomon JP, Benayed R, Hechtman JF, Ladanyi M. Identifying patients with NTRK fusion cancer. Ann Oncol. 2019;30(Suppl_8): viii16-viii22.
5. Drilon A. TRK inhibitors in TRK fusion-positive cancers. Ann Oncol. 2019;30(Suppl_8): viii23-viii30.
6. Center for Disease Control Manual. Guide: Safety Management, NO. CDC-22, Atlanta, GA. April 30, 1976 “Decontamination of Laboratory Sink Drains to Remove Azide Salts.”
7. Clinical and Laboratory Standards Institute (CLSI). Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline-Fourth Edition CLSI document M29-A4 Wayne, PA 2014.
